As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

The US FDA has accepted Novo Nordisk’s new drug application (NDA) submission for the 25 mg oral formulation of Wegovy ...

PLAINSBORO, N.J., May 1, 2025 /PRNewswire/ -- Today, Novo Nordisk announced that CVS ... preferred GLP-1 medicine on its largest commercial template formularies. This change will be effective ...

The e-methanol plant, built by European Energy & Mitsui, will supply companies including Maersk, LEGO & Novo Nordisk with ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on existing tariff and trade policies.

treatment on its template formularies starting 1 July. CVS’s decision is expected to expand access to Novo’s weight-loss therapy, whilst limiting coverage for Lilly’s Zepbound, potentially ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most ...

CVS Health Corporation ( NYSE: CVS) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial ...

Vienna, Austria – May 9th 2025 – Biomay, a leading manufacturer of recombinant proteins, today announced the commercial availability of its CRISPR/Cas9 nuclease, marking a significant addition to its ...

Long-read lengths (hundreds of base pairs or more) enable de novo sequencing and simplify ... The use of single-molecule templates translates into simplified template preparation and typically ...